Watanabe Wataru, Kuwabara Rika, Nakahara Toshinori, Hamasaki Osamu, Sakamoto Ikuo, Okada Koji, Minamoto Atsushi, Mishima Hiromu K
Department of Ophthalmology, Mazda Hospital, Hiroshima, Japan.
Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):1033-5. doi: 10.1007/s00417-002-0573-9. Epub 2002 Nov 9.
Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood. With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year. Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen. Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.
A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen.
He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.
When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity. It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects.
胶质母细胞瘤是一种发生于成年期大脑的恶性肿瘤。采用包括手术、放疗和化疗相结合的当前治疗方案,患者的平均预期寿命限制在约1年。因此,胶质母细胞瘤患者有时会在治疗方案中增加颈内动脉注射抗癌药。一般来说,卡铂据说比顺铂副作用更小,而顺铂的眼和眼眶毒性是众所周知的。然而,我们遇到了1例颈内动脉注射卡铂后发生严重眼和眼眶毒性的病例,此类报道并不常见。
一名58岁男性因左颞叶复发性胶质母细胞瘤接受了颈内动脉注射卡铂治疗。注射后30小时,他主诉同侧眼疼痛和视力障碍。出现了由卡铂毒性引起的各种眼部症状和体征。
注射后,他接受了6天的静脉注射皮质类固醇和甘油治疗。虽然继发于急性闭角型青光眼的眼压升高有所下降,眼痛减轻,但持续3周出现了不可避免的视乳头水肿和渗出性视网膜脱离。最终,6周后,出现了伴有视神经萎缩的弥漫性脉络膜视网膜萎缩,他的左眼视力丧失。
在进行颈内动脉注射卡铂时,我们必须意识到其潜在的致盲性眼毒性。建议开展进一步的研究和调查,以努力将此类严重副作用降至最低。